Bristol-Myers Squibb Co. (BMS) fell back in the immuno-oncology (I-O) pack last year after reporting that its blockbuster, Opdivo (nivolumab), failed to achieve statistically significant progression-free survival (PFS) in the phase III CHECKMATE-026 trial testing the PD-1 immune checkpoint inhibitor as a monotherapy vs. platinum-based chemo in patients with first-line non-small-cell lung cancer (NSCLC) whose tumors express PD-L1 at greater than 5 percent.